<DOC>
	<DOCNO>NCT00176033</DOCNO>
	<brief_summary>The aim study determine pharmacokinetics Kaletra™ ( HIV protease inhibitor lopinavir ritonavir ) different body compartment assess role four different drug transporter ( MDR , MRP1 , MRP2 BCRP ) tissue distribution two protease inhibitor . The latter study compare intracellular concentration peripheral blood mononuclear cell ( PBMCs ) total free plasma concentration healthy individual . These effect study single dose ( day 1 ) , steady state ( day 3 ) , chronic treatment ( day 14 ) .</brief_summary>
	<brief_title>Influence Drug Transporter Expression Pharmacokinetics HIV Protease Inhibitor Kaletra</brief_title>
	<detailed_description>Objective : Measurement AUC , Cmax , tmax , t1/2 clearance ( Cl ) protease inhibitor Kaletra™ ( lopinavir ritonavir ) plasma healthy individual - establish free total plasma - blood cell concentration-relationship - establish free total plasma - saliva concentration-relationship - establish blood cell concentration - drug transporter expression-relationship</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Good state health Drug treatment know inhibitor inducer cytochrome P450 isozymes ABCtransporters within precede 2 month Any acute chronic illness Smoking Pregnancy Alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>ritonavir</keyword>
	<keyword>lopinavir</keyword>
	<keyword>HIV Infections</keyword>
</DOC>